New Stock Tracker: bad year for medtech floats after credit crisis
This article was originally published in Clinica
Executive Summary
Over the last year, New Stock Tracker has been casting its eye over newly-listed medical device firms from all over the world and how they have performed on their respective markets. The noticeable success stories have been firms that have were capable of riding the shockwaves of the well-documented credit crisis – however, these were few and far between. All shares in this article relate to the respective companies’ share price at the close of market August 1.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals